1. Screening transplant donors for HTLV-1 and -2
- Author
-
Gallo, R. C., Willems, L., Hasegawa, H., Accolla, Roberto, Bangham, C., Bazarbachi, A., Bertazzoni, U., De Freitas Carneiro Proietti, A. B., Cheng, H., Chieco Bianchi, L., Ciminale, V., Gessain, A., Gotuzzo, E., Hall, W., Harford, J., Hermine, O., Jacobson, S., Macchi, B., Macpherson, C., Mahieux, R., Matsuoka, M., Mcsweegan, E., Murphy, E. L., Péloponèse, J. M., Reis, J., Simon, V., Tagaya, Y., Taylor, G. P., Watanabe, T., Yamano, Y., and Wellcome Trust
- Subjects
0301 basic medicine ,Male ,HTLV-1 infection ,viruses ,donor selection ,Review ,030230 surgery ,Biochemistry ,Myelopathy ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,Tropical spastic paraparesis ,1114 Paediatrics And Reproductive Medicine ,Human T-lymphotropic virus 1 ,tropical spastic paraparesis ,biology ,Human T-lymphotropic virus 2 ,organ transplantation ,Settore BIO/14 ,virus diseases ,Hematology ,Settore MED/07 - Microbiologia e Microbiologia Clinica ,HTLV-2 infection ,Paraparesis, Tropical Spastic ,Immunology ,Cell Biology ,purl.org/pe-repo/ocde/ford#3.01.03 [https] ,purl.org/pe-repo/ocde/ford#3.02.06 [https] ,Leukemia ,female ,priority journal ,breast milk ,Female ,organ donor ,blood transfusion ,1102 Cardiovascular Medicine And Haematology ,Donor Selection ,03 medical and health sciences ,blood ,medicine ,Humans ,human ,procedures ,nonhuman ,business.industry ,Donor selection ,Global Virus Network’s Task Force on HTLV-1 ,1103 Clinical Sciences ,medicine.disease ,biology.organism_classification ,nervous system diseases ,Lymphoma ,Transplantation ,030104 developmental biology ,HTLV-II Infections ,business - Abstract
Human T-cell leukemia virus-1 (HTLV-1) is the first pathogenic human retrovirus discovered in 1980.1 HTLV-1 causes 2 devastating diseases: adult T-cell leukemia/lymphoma (ATL) and a neurological disorder, HTLV-1–associated myelopathy/tropical spastic paraparesis (HAM/TSP or, more briefly, HAM). ATL becomes apparent in 2% to 5% of those infected with HTLV-1; another 1% to 2% will develop HAM.2 There are usually 2 to 3 decades of latency after the infection before the onset of symptoms. A second HTLV (HTLV-2) isolated in 1982 has been causally linked to HAM, but not ATL.3 In other cases, HTLV-1 and HTLV-2 infection may remain asymptomatic for years while being transmitted from person-to-person through host cells in body fluids and breast milk, blood cell transfusions, and solid organ transplantation. There are no licensed vaccines to prevent HTLV-1 or HTLV-2 infections.
- Published
- 2016